Covid-19 roundup: CanSi­no sub­mits vac­cine to Chi­nese reg­u­la­tors; As­traZeneca says an­ti­bod­ies show ear­ly ef­fi­ca­cy against new vari­ants — re­port

CanSi­no says their sin­gle-dose Covid-19 vac­cine is 65.28% ef­fec­tive at pre­vent­ing symp­to­matic Covid-19 cas­es, and they’ve of­fi­cial­ly filed for au­tho­riza­tion with Chi­na’s Na­tion­al Med­ical Prod­ucts …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER